0.2 ML adalimumab-adbm 50 MG/ML Prefilled Syringe [Cyltezo]

RxCUI: 2640892
RxNorm name: 0.2 ML adalimumab-adbm 50 MG/ML Prefilled Syringe [Cyltezo]
Display name: 0.2 ML adalimumab-adbm 50 MG/ML Prefilled Syringe [Cyltezo]
Full name: 0.2 ML adalimumab-adbm 50 MG/ML Prefilled Syringe [Cyltezo]
Term type: SBD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:47

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761058	Cyltezo	adalimumab-adbm	351(k) Interchangeable	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Cyltezo	ADALIMUMAB-ADBM	Boehringer Ingelheim Pharmaceuticals, Inc.	115ea79b-7209-7f19-b35d-36ec0828fbf5	2026-05-22	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2640892

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
115ea79b-7209-7f19-b35d-36ec0828fbf5	CYLTEZO 10 MG in 0.2 ML Prefilled Syringe [PSN] · 0.2 ML adalimumab-adbm 50 MG/ML Prefilled Syringe [Cyltezo] [SBD] · 0.2 ML Cyltezo 50 MG/ML Prefilled Syringe [SY] · Cyltezo 10 MG per 0.2 ML Prefilled Syringe [SY]	4	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303